Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
On "24/10/2024", the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "MHRA reminds healthcare professionals to advise patients of the side effects of GLP-1 agonists and to report misuse". GLP-1 receptor agonists are used to treat type 2 diabetes and obesity, carrying a risk of gastrointestinal side effects. Patients should be aware of these risks and report any adverse reactions via the Yellow Card scheme.
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
